# Cefprozil 500 mg Tablets Under Fasting Conditions

> **NCT00840281** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 38 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Cefzil® 500 mg tablets
- **DRUG:** Cefprozil 500 mg Tablets

## Key facts

- **NCT ID:** NCT00840281
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2003-09
- **Final completion:** 2003-09
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00840281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00840281, "Cefprozil 500 mg Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00840281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*